Novel approaches in melanoma prevention and therapy

Cancer Treatment and Research

Volumn 159, Issue , 2014, Pages 443-455

  Grimaldi, Antonio M ^a   Cassidy, Pamela B ^b   Leachmann, Sancy ^b   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

BRAF; Dabrafenib; Ipilimumab; Melanoma; Vemurafenib

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CHIR 265; COBIMETINIB; DABRAFENIB; DACARBAZINE; ENCORAFENIB; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; INTERLEUKIN 2; IPILIMUMAB; LYCOPENE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ACRAL MELANOMA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARM MELANOMA; ARTHRALGIA; ARTICLE; BRAF GENE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; DIET THERAPY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; GENE MUTATION; HEREDITY; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; KERATOACANTHOMA; MACULAR RASH; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSAL MELANOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CARCINOMA; SKIN DISEASE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRUNK MELANOMA; TUMOR MICROENVIRONMENT; ULTRAVIOLET RADIATION; UVEA MELANOMA; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY;

EID: 84896117104     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38007-5_25     Document Type: Article

References (37)

1. Lazovich DA, Vogel RI, Berwick M, Weinstock MA, Anderson KE, Warshaw EM (2010). Indoor tanning and Risk of Melanoma: A case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 19(6):1557–1568.
2. Pho L, Grossman D, Leachman SA (2006) Melanoma genetics: a review of genetic factors and clinical phenotypesin familian melanomas. Curr Opin Oncol 18(2):173–179
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648
4. Gruijl FR (2003) IL-40 UV carcinogenesis and melanocytes. Pigment Cell Res 16:591
5. Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) On behalf of the WHO international agency for research on cancer monograph working group. Special report: policy a review of human carcinogens—Part D: radiation. Lancet Oncol, 10(8):751–752
6. WHO (2006) International agency for fresearch on cancer. exposure to artificial UV radiation and skin cancer. IARC working group reports. Vol 1
7. Meyskens FL, Jr McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI (2001) Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 31:799–808
8. Rizwan M, Rodriguez-Blanco I, Harbottle A, Birch-Machin MA, Watson RE, Rhodes LE (2011) Tomato paste rich in lycopene protects against cutaneous photo damage in humans in vivo: a randomized controlled trial. Br J Dermatol 164:154–162
9. Talalay P, Fahey JW, Healy ZR, Wehage SL, Benedict AL, Min C, Dinkova-Kostova AT (2007) Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc Natl Acad Sci USA 104: 17500–17505
10. Dinkova-Kostova AT, JW Fahey, AL Benedict, SN Jenkins, L Ye, SL Wehage, P Talalay (2010) Dietary glucoraphanin-rich broccoli sprout extracts protect against UV radiationinduced skin carcinogenesis in SKH-1 hairless mice. Photochemical and Photobiological Sciences 9: 597–600
11. Nichols JA, Katyar SK (2010) Skin photoprotection and natural polyphenol:antiinflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 302(2):71–83
12. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, Shimokawa R (1992) Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65:51–54
13. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885
14. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88(9):4393–4397. doi:10.1210/jc.2003-030305.PMID12970315
15. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med, 353:2135–2147
16. Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt HM, Martin AM, Herlyn M, Lessin SR, Weber BL (2004) Absence of BRAF mutations in UVprotected mucosal melanomas. J Med Genet 41:270–272
17. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe’er J, Sidransky D (2003) Lack of BRAF mutation in primary uveal melanoma invest. Ophthalmol Vis Sci, 44:72876–2878
18. Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. cancer res, 63(18):5761–5766
19. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC (2003) Determinants of BRAF Mutations in Primary Melanomas. J Natl Cancer Inst 95(24):1878–1890
20. Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30:3477–3488
21. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. JCO April 1, 29(10):1239–1246
22. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res, 11(1):75–81
23. Tarhini AA, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 3:15–25
24. Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 8:848–861
25. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599
26. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819
27. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib. N Engl J Med 366:707–714
28. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
29. Kefford R et al (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28:15 s, (suppl; abstr 8503)
30. Amiri P, Aikawa ME, Dove J et al (2006) CHIR-265 is a potent selective inhibitor of c-Raf/ B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with RAS/RAF pathway mutations. Proc Am Assoc Cancer Res, 47 (Abstract 4855)
31. Stuart DD, Li N, Poon DJ, Aardalen K, Kaufman S, Merritt H, Salangsang F, Lorenzana E, Li A, Ghoddusi M, Caponigro G, Sun F, Kulkarni S, Kakar S, Turner N, Zang R, Tellew J, Pryer N. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor.#3790
32. http://www.cancertrialsaustralia.com/Clinical-Trials-Register.aspx. Cancer Trials Australia
33. http://clinicaltrials.gov/ct2/show/NCT01400451?term=Vemurafinib&rank=5.U.S. NIH
34. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (2010) PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23:190–200
35. Infante JR et al (2011) Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29: (suppl; abstr CRA8503)
36. Niehr et al (2011) Combination therapy with Vemurafinib (PLX4032/RG7204) and Metformin in melanoma cell lines with distinct driver mutations. J Trans Med, 9:76
37. Ascierto PA, Streicher HZ, Sznol M (2010) Melanoma: a model for testing new agents in combination therapies. J Trans Med 8:38